321 related articles for article (PubMed ID: 29703842)
21. Proteasome-associated cysteine deubiquitinases are molecular targets of environmental optical brightener compounds.
Castro I; Ekinci E; Huang X; Cheaito HA; Ahn YH; Olivero-Verbel J; Dou QP
J Cell Biochem; 2019 Aug; 120(8):14065-14075. PubMed ID: 30963630
[TBL] [Abstract][Full Text] [Related]
22. Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells.
Garay T; Kenessey I; Molnár E; Juhász É; Réti A; László V; Rózsás A; Dobos J; Döme B; Berger W; Klepetko W; Tóvári J; Tímár J; Hegedűs B
PLoS One; 2015; 10(2):e0117021. PubMed ID: 25646931
[TBL] [Abstract][Full Text] [Related]
23. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
24. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE
Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987
[TBL] [Abstract][Full Text] [Related]
25. Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma.
Jiang L; Sun Y; Wang J; He Q; Chen X; Lan X; Chen J; Dou QP; Shi X; Liu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):453. PubMed ID: 31694672
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy.
Talebi A; de Laat V; Spotbeen X; Dehairs J; Rambow F; Rogiers A; Vanderhoydonc F; Rizotto L; Planque M; Doglioni G; Motamedi S; Nittner D; Roskams T; Agostinis P; Bechter O; Boecxstaens V; Garmyn M; O'Farrell M; Wagman A; Kemble G; Leucci E; Fendt SM; Marine JC; Swinnen JV
J Exp Clin Cancer Res; 2023 Apr; 42(1):92. PubMed ID: 37072838
[TBL] [Abstract][Full Text] [Related]
27. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
28. Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma.
Potu H; Peterson LF; Kandarpa M; Pal A; Sun H; Durham A; Harms PW; Hollenhorst PC; Eskiocak U; Talpaz M; Donato NJ
Nat Commun; 2017 Feb; 8():14449. PubMed ID: 28198367
[TBL] [Abstract][Full Text] [Related]
29. Inactivation of USP14 Perturbs Ubiquitin Homeostasis and Delays the Cell Cycle in Mouse Embryonic Fibroblasts and in Fruit Fly Drosophila.
Lee JH; Park S; Yun Y; Choi WH; Kang MJ; Lee MJ
Cell Physiol Biochem; 2018; 47(1):67-82. PubMed ID: 29763934
[TBL] [Abstract][Full Text] [Related]
30. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF
Mielczarek-Lewandowska A; Sztiller-Sikorska M; Osrodek M; Czyz M; Hartman ML
Apoptosis; 2019 Aug; 24(7-8):596-611. PubMed ID: 30989459
[TBL] [Abstract][Full Text] [Related]
31. ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.
Eichhoff OM; Stoffel CI; Käsler J; Briker L; Turko P; Karsai G; Zila N; Paulitschke V; Cheng PF; Leitner A; Bileck A; Zamboni N; Irmisch A; Balazs Z; Tastanova A; Pascoal S; Johansen P; Wegmann R; Mena J; Othman A; Viswanathan VS; Wenzina J; Aloia A; Saltari A; Dzung A; ; Krauthammer M; Schreiber SL; Hornemann T; Distel M; Snijder B; Dummer R; Levesque MP
Cancer Res; 2023 Apr; 83(7):1128-1146. PubMed ID: 36946761
[TBL] [Abstract][Full Text] [Related]
32. A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.
Galbán S; Apfelbaum AA; Espinoza C; Heist K; Haley H; Bedi K; Ljungman M; Galbán CJ; Luker GD; Dort MV; Ross BD
Mol Cancer Ther; 2017 Nov; 16(11):2340-2350. PubMed ID: 28775144
[TBL] [Abstract][Full Text] [Related]
33. A ubiquitinome analysis to study the functional roles of the proteasome associated deubiquitinating enzymes USP14 and UCH37.
van der Wal L; Bezstarosti K; Demmers JAA
J Proteomics; 2022 Jun; 262():104592. PubMed ID: 35489684
[TBL] [Abstract][Full Text] [Related]
34.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
35. Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy.
Talebi A; Dehairs J; Rambow F; Rogiers A; Nittner D; Derua R; Vanderhoydonc F; Duarte JAG; Bosisio F; Van den Eynde K; Nys K; Pérez MV; Agostinis P; Waelkens E; Van den Oord J; Fendt SM; Marine JC; Swinnen JV
Nat Commun; 2018 Jun; 9(1):2500. PubMed ID: 29950559
[TBL] [Abstract][Full Text] [Related]
36. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
37. Refining Targeted Therapy Opportunities for
Jenkins RW; Barbie DA
Cancer Discov; 2017 Aug; 7(8):799-801. PubMed ID: 28765115
[TBL] [Abstract][Full Text] [Related]
38. A new gold(I) complex-Au(PPh
Li X; Huang Q; Long H; Zhang P; Su H; Liu J
EBioMedicine; 2019 Jan; 39():159-172. PubMed ID: 30527624
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment.
Read J
Australas J Dermatol; 2013 Aug; 54(3):163-72. PubMed ID: 23330781
[TBL] [Abstract][Full Text] [Related]
40. Ubiquitinated proteins promote the association of proteasomes with the deubiquitinating enzyme Usp14 and the ubiquitin ligase Ube3c.
Kuo CL; Goldberg AL
Proc Natl Acad Sci U S A; 2017 Apr; 114(17):E3404-E3413. PubMed ID: 28396413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]